Home Newsfeeds Barclays Downgrades Azul to Underweight, Lowers Price Target to $7

Barclays Downgrades Azul to Underweight, Lowers Price Target to $7

Barclays analyst Pablo Monsivais downgrades Azul (NYSE:AZUL) from Equal-Weight to Underweight and lowers the price target from $17 to $7.

byBenzinga Newsdesk

July 6, 2022

1 minute read

Barclays analyst Pablo Monsivais downgrades Azul (NYSE:AZUL) from Equal-Weight to Underweight and lowers the price target from $17 to $7.

If You Invested $100 In This Stock 15 Years Ago, You Would Have $400 Today

By Benzinga Insights

January 27, 3:32 PM

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 15 years by 1.47% on an annualized basis…

GILD

News

‘Texas House Approves Bill To Allow Medical Marijuana As Opioid Alternative And Replace THC Limit’ – Marijuana Moment

By Happy Mohamed

April 11, 12:50 PM

https://www.marijuanamoment.net/texas-house-approves-bill-to-allow-medical-marijuana-as-opioid-alternative-and-replace-thc-limit/ The Texas House of Representatives has given initial approval a bill that would allow

ACB

Clover Health Investments Q2 Sales $846.70M Beat $814.62M Estimate

By Bill Haddad

August 8, 4:22 PM

Clover Health Investments (NASDAQ:CLOV) reported quarterly sales of $846.70 million which beat the analyst consensus estimate of $814.62 million by 3.94 percent. This is a 105.27 percent increase over sales of $412.47

CLOV

Lilly Receives U.S. FDA Fast Track Designation For Tirzepatide For The Treatment Of Adults With Obesity, Or Overweight With Weight-related Comorbidities

By Benzinga Newsdesk

October 6, 6:45 AM

Eli Lilly and Company (NYSE:LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of tirzepatide for the treatment of adults with obesity, or

LLY

Barclays Downgrades Azul to Underweight, Lowers Price Target to $7

Related Posts

If You Invested $100 In This Stock 15 Years Ago, You Would Have $400 Today

‘Texas House Approves Bill To Allow Medical Marijuana As Opioid Alternative And Replace THC Limit’ – Marijuana Moment

Clover Health Investments Q2 Sales $846.70M Beat $814.62M Estimate

Lilly Receives U.S. FDA Fast Track Designation For Tirzepatide For The Treatment Of Adults With Obesity, Or Overweight With Weight-related Comorbidities